Skip to main content
Year archive

Camurus — 2023 filings

All 32 regulatory filings released by Camurus (CAMX) in 2023, sourced directly from the official regulator.

32 Filings
2023 Period
2023 filings (32)
Filing Released Lang
Förändring av antalet aktier och röster i Camurus
Share Issue/Capital Change
2023-12-29 Swedish
Change in number of shares and votes in Camurus
Share Issue/Capital Change
2023-12-29 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-04 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q3 2023
2023-11-09 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q3 2023
2023-11-09 English
Camurus raises financial guidance for the full year 2023
Earnings Release 9M 2023
2023-10-23 English
Camurus höjer finansiella utsikten för helåret 2023
Earnings Release Q3 2023
2023-10-23 Swedish
Camurus’ Nomination Committee appointed for the Annual General Meeting 2024
Board/Management Information
2023-10-18 English
Valberedning utsedd inför Camurus årsstämma 2024
Board/Management Information
2023-10-18 Swedish
Förändring av antalet aktier och röster i Camurus
Declaration of Voting Results & Voting Rights Announcements
2023-08-31 Swedish
Change in number of shares and votes in Camurus
Share Issue/Capital Change
2023-08-31 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-07-18 Swedish
Earnings Release 2023
Earnings Release Q2 2023
2023-07-18 English
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Earnings Release FY 2023
2023-07-17 English
Camurus meddelar nya fas 3-data som styrker långtidssäkerhet och behandlingseffekt av oktreotid subkutan depå (CAM2029) i patienter med akromegali
Regulatory Filings
2023-07-17 Swedish
Camurus oktreotid subkutan depå (CAM2029) visar positiva resultat i placebokontrollerad fas 3-studie i patienter med akromegali
Regulatory Filings
2023-06-20 Swedish
Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial
Earnings Release FY 2023
2023-06-20 English
Change in number of shares and votes in Camurus
Share Issue/Capital Change
2023-05-31 English
Förändring av antalet aktier och röster i Camurus
Share Issue/Capital Change
2023-05-31 Swedish
Camurus meddelar FDA-godkännande av Brixadi™ för behandling av opioidberoende
Regulatory Filings
2023-05-23 Swedish
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
Regulatory Filings
2023-05-23 English
Resolutions at the annual general meeting 2023 in Camurus
AGM Information
2023-05-10 English
Beslut vid Camurus årsstämma 2023
AGM Information
2023-05-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-10 English
Kallelse till årsstämma 2023 i Camurus AB (publ)
AGM Information
2023-04-04 Swedish
Notice of annual general meeting 2023 in Camurus AB (publ)
AGM Information
2023-04-04 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-03-30 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q4 2022
2023-02-14 Swedish
Audit Report / Information 2022
Audit Report / Information FY 2022
2023-02-14 English
Camurus withdraws variation application for CAM2038 to include chronic pain
Regulatory Filings
2023-02-13 English
Camurus drar tillbaka ändringsansökan för CAM2038 till att omfatta kronisk smärta
Regulatory Filings
2023-02-13 Swedish